A Phase I Dose Escalation Study of the Safety, Tolerability and Pharmacokinetics of SCT200, a Recombinant Full Human Anti-epidermal Growth Factor Receptor(EGFR) Monoclonal Antibody in Patients With Metastatic Colorectal Cancer Following Fluoropyrimidine, Irinotecan and Oxaliplatine Chemotherapy Regiment

Trial Profile

A Phase I Dose Escalation Study of the Safety, Tolerability and Pharmacokinetics of SCT200, a Recombinant Full Human Anti-epidermal Growth Factor Receptor(EGFR) Monoclonal Antibody in Patients With Metastatic Colorectal Cancer Following Fluoropyrimidine, Irinotecan and Oxaliplatine Chemotherapy Regiment

Recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Apr 2017

At a glance

  • Drugs SCT 200 (Primary)
  • Indications Colorectal cancer
  • Focus Adverse reactions
  • Sponsors Sinocelltech
  • Most Recent Events

    • 08 Apr 2015 Status changed from active, no longer recruiting to recruiting, as reported by ClinicalTrials.gov.
    • 13 Jan 2015 According to the ClinicalTrials.gov record, status changed from not yet recruiting to active, no longer recruiting.
    • 13 Aug 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top